FR10C0056I2 - - Google Patents

Info

Publication number
FR10C0056I2
FR10C0056I2 FR10C0056C FR10C0056C FR10C0056I2 FR 10C0056 I2 FR10C0056 I2 FR 10C0056I2 FR 10C0056 C FR10C0056 C FR 10C0056C FR 10C0056 C FR10C0056 C FR 10C0056C FR 10C0056 I2 FR10C0056 I2 FR 10C0056I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0056C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0056(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon NV filed Critical Organon NV
Publication of FR10C0056I1 publication Critical patent/FR10C0056I1/fr
Application granted granted Critical
Publication of FR10C0056I2 publication Critical patent/FR10C0056I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR10C0056C 1994-03-02 2010-12-23 Active FR10C0056I2 (enrdf_load_html_response)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition
EP95912188A EP0746317B1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition

Publications (2)

Publication Number Publication Date
FR10C0056I1 FR10C0056I1 (enrdf_load_html_response) 2011-01-28
FR10C0056I2 true FR10C0056I2 (enrdf_load_html_response) 2011-11-25

Family

ID=8216678

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0056C Active FR10C0056I2 (enrdf_load_html_response) 1994-03-02 2010-12-23

Country Status (22)

Country Link
US (1) US5763476A (enrdf_load_html_response)
EP (1) EP0746317B1 (enrdf_load_html_response)
JP (2) JP4099224B2 (enrdf_load_html_response)
KR (1) KR100330942B1 (enrdf_load_html_response)
CN (1) CN1079670C (enrdf_load_html_response)
AT (1) ATE167057T1 (enrdf_load_html_response)
AU (1) AU692530B2 (enrdf_load_html_response)
BR (2) BR9506924A (enrdf_load_html_response)
CA (1) CA2182981C (enrdf_load_html_response)
CZ (1) CZ284633B6 (enrdf_load_html_response)
DE (2) DE122010000050I2 (enrdf_load_html_response)
DK (1) DK0746317T3 (enrdf_load_html_response)
ES (1) ES2118584T3 (enrdf_load_html_response)
FI (1) FI117923B (enrdf_load_html_response)
FR (1) FR10C0056I2 (enrdf_load_html_response)
HU (1) HU225051B1 (enrdf_load_html_response)
LU (1) LU91751I2 (enrdf_load_html_response)
NO (2) NO308772B1 (enrdf_load_html_response)
NZ (1) NZ282394A (enrdf_load_html_response)
PL (1) PL180465B1 (enrdf_load_html_response)
RU (1) RU2139051C1 (enrdf_load_html_response)
WO (1) WO1995023600A1 (enrdf_load_html_response)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
CA2476250C (en) * 2002-02-13 2010-08-03 Michael K. Weibel Drug dose-form and method of manufacture
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
JP2006528676A (ja) * 2003-05-16 2006-12-21 ファイザー・プロダクツ・インク 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
US8617467B2 (en) * 2003-09-22 2013-12-31 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
WO2006040314A1 (en) * 2004-10-15 2006-04-20 Pfizer Inc. Treatment of bipolar disorders and associated symptoms
PL1917267T3 (pl) * 2005-04-07 2009-06-30 Merck Sharp & Dohme Postać krystaliczna maleinianu asenapiny
BRPI0610677A2 (pt) 2005-04-07 2012-10-30 Organon Nv derivado de trans-aminoácido, e, processos para a preparação do mesmo e para a preparação de asenapina
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
CA2766291C (en) 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
TW201118102A (en) 2009-07-29 2011-06-01 Organon Nv Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
AU2011268335A1 (en) 2010-06-18 2013-01-10 Dr. Reddy's Laboratories Ltd. Asenapine maleate
EP2598496B1 (en) 2010-07-29 2014-03-19 Laboratorios Lesvi, S.L. Novel process for the preparation of asenapine
WO2012038975A2 (en) * 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
CN103313712B (zh) 2010-11-15 2016-10-26 艾吉因生物股份有限公司 用于治疗认知障碍的哒嗪衍生物、组合物和方法
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
US9505771B2 (en) * 2011-05-18 2016-11-29 Laboratories Lesvi S.L. Stable micronised monoclin form of asenapine maleate and its synthesis
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
CN105007899A (zh) 2012-12-20 2015-10-28 卡希夫制药有限责任公司 用于提高生物利用度的口腔崩解片制剂
CN103893139B (zh) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (enrdf_load_html_response) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2015125152A2 (en) * 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi THIN FILM STRIP OF ASENAPINE
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
MX384734B (es) 2015-06-19 2025-03-14 Agenebio Inc Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
IL309536B2 (en) 2016-01-26 2025-07-01 Intra Cellular Therapies Inc Pharmaceutical preparation for injection containing (Sa10, Rb6)-3-)8-(4-fluorophenoxy)propyl)-b6, 7, 8, 9, 10, 10a- hexahydro-H1- pyrido[3',4' :4,5]pyrrolo[1,2,3 -de]quinoxalin-2(H3)-one
ES2879888T3 (es) 2016-03-25 2021-11-23 Intra Cellular Therapies Inc Compuestos orgánicos y su uso en el tratamiento o prevención de trastornos del sistema nervioso central
US10085971B2 (en) * 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
JP7236389B2 (ja) 2016-12-20 2023-03-09 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
CN116327770A (zh) 2017-03-24 2023-06-27 细胞内治疗公司 新组合物和方法
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
MX2020009928A (es) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Compuestos organicos.
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
EP3993798A4 (en) 2019-07-07 2023-04-26 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (en) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Intraoral formulated trifluorobenzodiazepines and the use thereof
ATE212235T1 (de) * 1991-04-08 2002-02-15 Sumitomo Pharma Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation

Also Published As

Publication number Publication date
NO2010024I1 (no) 2011-01-03
DE69502939T2 (de) 1998-10-22
CA2182981A1 (en) 1995-09-08
NO963639L (no) 1996-10-30
EP0746317B1 (en) 1998-06-10
CN1143320A (zh) 1997-02-19
HUT76319A (en) 1997-08-28
NO963639D0 (no) 1996-08-30
DK0746317T3 (da) 1999-03-22
HK1008417A1 (en) 1999-05-07
BR9506924A (pt) 1997-09-30
ES2118584T3 (es) 1998-09-16
FR10C0056I1 (enrdf_load_html_response) 2011-01-28
AU1947895A (en) 1995-09-18
CZ284633B6 (cs) 1999-01-13
WO1995023600A1 (en) 1995-09-08
JP2006342178A (ja) 2006-12-21
CA2182981C (en) 2006-10-17
CZ254196A3 (en) 1997-10-15
FI963398L (fi) 1996-08-30
FI117923B (fi) 2007-04-30
EP0746317A1 (en) 1996-12-11
ATE167057T1 (de) 1998-06-15
RU2139051C1 (ru) 1999-10-10
JP4099224B2 (ja) 2008-06-11
HU9602383D0 (en) 1996-10-28
AU692530B2 (en) 1998-06-11
LU91751I2 (fr) 2011-01-04
FI963398A0 (fi) 1996-08-30
NO2010024I2 (no) 2012-04-10
DE122010000050I2 (de) 2011-07-21
JPH09509674A (ja) 1997-09-30
US5763476A (en) 1998-06-09
MX9603713A (es) 1997-12-31
DE69502939D1 (de) 1998-07-16
CN1079670C (zh) 2002-02-27
NO308772B1 (no) 2000-10-30
PL316080A1 (en) 1996-12-23
DE122010000050I1 (de) 2011-05-05
HU225051B1 (en) 2006-05-29
BR1100625A (pt) 1999-12-28
KR100330942B1 (ko) 2002-11-16
NZ282394A (en) 1997-12-19
JP4616810B2 (ja) 2011-01-19
PL180465B1 (pl) 2001-02-28

Similar Documents

Publication Publication Date Title
FR2722392B1 (enrdf_load_html_response)
FR10C0056I2 (enrdf_load_html_response)
TW284868B (enrdf_load_html_response)
EP0666525A3 (enrdf_load_html_response)
BRPI9507160A (enrdf_load_html_response)
EP0669187A3 (enrdf_load_html_response)
BR9509661A (enrdf_load_html_response)
EP0670326A3 (enrdf_load_html_response)
EP0667627A3 (enrdf_load_html_response)
BY1704C1 (enrdf_load_html_response)
TW284861B (enrdf_load_html_response)
EP0717033A3 (enrdf_load_html_response)
ITMI952211A0 (enrdf_load_html_response)
DK0685247T3 (enrdf_load_html_response)
BR7402039U (enrdf_load_html_response)
CU22450A3 (enrdf_load_html_response)
ECSDI940183S (enrdf_load_html_response)
BR7402097U (enrdf_load_html_response)
IN182314B (enrdf_load_html_response)
CN3026925S (enrdf_load_html_response)
EP0686685A3 (enrdf_load_html_response)
CN3026648S (enrdf_load_html_response)
EP0669667A3 (enrdf_load_html_response)
EP0669657A3 (enrdf_load_html_response)
CN3025860S (enrdf_load_html_response)